International Biotechnology Trust plc specializes in investments in development stage and late stage companies. The majority of the fund’s assets are generally invested in smaller and mid-capitalization quoted companies, with a minority in larger capitalization quoted companies. It makes long only investments. It prefers to invest in quoted or unquoted biotechnology and life sciences companies focused on drug discovery and development and in related sectors such as microbiology, life sciences, pharmaceutical research and development, gene research and development, medical devices or healthcare services. The fund seeks to invest in companies engaged in development and/or commercialization of ...
London, WC2B 6ST
Founded in 1994
International Biotechnology Trust plc Announces Audited Group Earnings Results for the Year Ended August 31, 2014
Nov 3 14
International Biotechnology Trust plc announced audited group earnings results for the year ended August 31, 2014. For the period, the company reported profit before finance costs and tax of £44,863,000 compared to £44,479,000 a year ago. profit on ordinary activities before tax was £44,754,000 compared to £44,466,000 a year ago. profit for the year attributable to owners of the parent company was £44,719,000 or 81.30 pence per basic and diluted share compared to £44,428,000 or 80.30 pence per basic and diluted share a year ago. Net cash flows used in operating activities were £2,231,000 compared to £21,000 a year ago.
International Biotechnology Trust Seeks Acquisitions
Nov 3 14
International Biotechnology Trust plc (LSE:IBT) is looking for acquisition opportunities. This has been a major driving force of mergers and acquisitions within the sector and is set to continue.
International Biotechnology Trust plc, Annual General Meeting, Nov 24, 2014
May 19 14
International Biotechnology Trust plc, Annual General Meeting, Nov 24, 2014., at 14:30 GMT Standard Time. Location: BNP Paribas Fortis.